Why the study?
Iron deficiency is common in heart failure and associated with poor functional outcomes, increased hospitalizations, and higher mortality, motivating an evaluation of intravenous ferric carboxymaltose efficacy.
Does intravenous ferric carboxymaltose reduce recurrent hospitalizations for heart failure or cardiovascular death in patients with heart failure and iron deficiency?
Population
6493 HF patients with iron deficiency across 11 RCTs
Comparison
Intravenous ferric carboxymaltose vs placebo or standard care
Design
Systematic review and meta-analysis of RCTs with trial sequential analysis
Follow-up
1-year and complete follow-up
Key result
Intravenous ferric carboxymaltose reduced recurrent heart failure hospitalizations or cardiovascular death by 27% at 1-year compared to control (RR 0.73).
Authors
Loading...
Supports intravenous ferric carboxymaltose in iron-deficient heart failure; confirms benefit on recurrent events in meta-analysis of RCTs.
Does intravenous ferric carboxymaltose reduce recurrent hospitalizations for heart failure or cardiovascular death in patients with heart failure and iron deficiency?
Intravenous ferric carboxymaltose significantly reduces the composite of recurrent heart failure hospitalizations or cardiovascular death and improves functional capacity in patients with heart failure and iron deficiency.
Ahmed et al. (2026) studied this question. Intravenous ferric carboxymaltose reduced recurrent heart failure hospitalizations or cardiovascular death by 27% at 1-year compared to control (RR 0.73).